LAVAL, QC, Aug. 9 /PRNewswire-FirstCall/ - LAB International Inc. ("LAB"), an integrated drug development company focused on developing therapies for the inhalation market, today announced it has completed patient enrollment in its LAB CGRP Phase IIa trial. No serious adverse events have been reported in any of the patients dosed. In accordance to previously disclosed timelines, the Company expects to have results from the study available by the end of the third quarter of 2006.
The objectives of this randomized, double blind, cross-over Phase II study were to investigate the protective efficacy of LAB CGRP on metacholine induced bronchial hyper-responsiveness in adult patients with mild to moderate asthma, to compare this efficacy to salbutamol and placebo and to evaluate the safety and tolerability of LAB CGRP in asthma patients. The trial has enrolled a total of 12 patients.
"The completion of patient enrollment in our first Phase II trial for LAB CGRP brings us one step closer to demonstrating efficacy in adult asthma patients. We are happy to report that as expected LAB CGRP continued to present an excellent safety profile. If positively demonstrated, the bronchodilatory, anti-inflammatory and broncho-protective properties in patients would represent a significant benefit over the usual combination asthma therapies." commented Dr. Halvor Jaeger, CEO of LAB International.
About LAB CGRP
LAB CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties.
About LAB International
LAB is an integrated drug development company focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies.
LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with 73.2 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
LAB INTERNATIONAL INC.CONTACT: visit LAB's website at www.labinc.ca, or contact: FredericDumais, Vice-President, Investor Relations, (450) 973-2240 ext. 1207, Fax:(450) 973-2259, dumaisf@labinc.ca
